Results 161 to 170 of about 28,950 (250)

Factors requiring adaptive re-planning in carbon ion radiotherapy for head and neck cancers. [PDF]

Front Oncol
Yamada T, Okano N, Matsumura A, Sakai M, Shimada H, Musha A, Ohno T.   +6 more
europepmc   +1 more source

Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Osteoporosis is a prevalent skeletal disorder characterised by progressive reduction in bone mass, microarchitectural deterioration, and increased fracture susceptibility. In India, approximately one‐third of the elderly population is affected by bone‐related disorders, and the global burden of osteoporosis continues to rise.
Pramoda G., Kamini Shivhare, Piyush Kumar Gupta, Amirhossein Sahebkar, Prashant Kesharwani, Rahul Shukla   +5 more
wiley   +1 more source

Evaluation and implementation of an independent Kilovoltage X-ray-based imaging platform for carbon ion radiotherapy. [PDF]

J Appl Clin Med Phys
Guo Y, Liu Z, Zhu Q, Cai M, Cai H, Liu R, Zhang Q, Xu Z.   +7 more
europepmc   +1 more source

Inhibitory Activity of Conferone on FAK Activity and Glutamine Metabolism in Human Colorectal Cancer

Journal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Colorectal cancer (CRC) is a major global cause of death, with metastases and chemotherapy resistance contributing to poor outcomes. To identify natural compounds with anticancer potential against CRC and elucidate their action mechanisms, the cytotoxicity of 37 natural compounds was evaluated against the HCT116, leading to the identification ...
Hien Thi My Ong, Eda Ates, Jaeyong Jung, Jeong Soo Sung, Jae‐Chul Pyun, Min‐Jung Kang   +5 more
wiley   +1 more source

Commissioning and robustness evaluation of external laser sensor for respiratory gating in carbon-ion radiotherapy. [PDF]

J Appl Clin Med Phys
Kim TH, Han S, Yoo D, Lee S, Oh T, Lee D, Kim C, Han MC, Hong CS, Kim JS.   +9 more
europepmc   +1 more source

Carbon Ion Radiotherapy - Chiba Experience

Carbon Ion Radiotherapy - Chiba Experience
Carbon ion radiotherapy (CIRT) is a unique radiotherapy, which possesses well localized and superior depth dose distribution in addition to uniform, less repairable radiobiological effects. The use of CIRT for various diseases has been explored as clinical trials at the Heavy Ion Medical Accelerator in Chiba (HIMAC), Japan, since 1994.
openaire  

In Vitro Evaluation of PARP1 Inhibitor Olaparib‐Cyanine Dye Conjugate for the Treatment of Glioblastoma

ChemMedChem, Volume 21, Issue 8, 28 April 2026.
Inhibition of DNA damage repair is a common mechanism to induce cancer cell death and, therefore, to treat cancers such as breast, prostate and ovarian cancer. This approach, although very attractive, has not been feasible for treating brain tumours due to the stringent structural features necessary for pharmaceutical agents to cross the blood–brain ...
Carina Dumo, Faheem, Peter J. Choi, Nicholas J. Pederson, Yuge Liu, Mike Dragunow, Thomas I‐H. Park, Katharine L. Diehl, Jiney Jose   +8 more
wiley   +1 more source

Carbon Ion Radiotherapy for Retroperitoneal Sarcoma: A Single-Institution Study. [PDF]

Cancers (Basel)
Imai R, Yonemoto T, Araki N, Takiyama H, Ikawa H, Yamada S, Ishikawa H.   +6 more
europepmc   +1 more source

Computational and Spectroscopic Insights Into the Rice Bran Derived Glu‐Gln‐Arg‐Pro‐Arg Pentapeptide as an Anticancer Agent: A DFT, Molecular Docking, and Molecular Dynamics Study

International Journal of Quantum Chemistry, Volume 126, Issue 8, April 15, 2026.
Rice bran–derived neutral EQRPR (L‐Glu‐L‐Gln‐L‐Arg‐L‐Pro‐L‐Arg) pentapeptide was structurally and biologically characterized using DFT calculations, vibrational spectroscopy, molecular docking, and molecular dynamics simulations. The DFT/wb97xd/6–31++G(d,p) level of theory showed the best agreement with the experimental spectra.
Gozde Yilmaz, Sefa Celik, Aysen E. Ozel, Sevim Akyuz   +3 more
wiley   +1 more source

Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization. [PDF]

ESMO Gastrointest Oncol
Sekiguchi Y, Shibuya K, Tomogane S, Miyasaka Y, Kakizaki S, Okamoto M, Araki K, Shirabe K, Ohno T.   +8 more
europepmc   +1 more source